TrialNature communications2024

The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial.

Juan Jose Rodriguez-Sevilla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.